CATX - Perspective Therapeutics, Inc.
NEXT EARNINGS:
Mar 25, 2026
(in 28 days)
EPS Est: $-0.36
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.25
DETAILS
HIGH:
$16.00
LOW:
$7.00
MEDIAN:
$13.00
CONSENSUS:
$12.25
UPSIDE:
126.01%
Market Cap:
402.83M
Volume:
2,016,310
Avg Volume:
3,411,028
52 Week Range:
1.6-6.16
Sector:
Healthcare
Industry:
Medical - Devices
Beta:
1.79
Last Dividend:
$N/A
Exchange:
AMEX
Country:
US
Employees:
138
IPO Date:
2005-11-10
EPS (TTM):
-1.23
P/E Ratio:
-2.59
Revenue (TTM):
N/A
Total Assets:
341.10M
Total Debt:
4.06M
Cash & Equiv:
61.58M
Rev Growth (5Y):
-100.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-25.2%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-0.35 | $-0.33 | -6.1% | $209000 | $232480 | -10.1% |
| 2025-08-13 | $-0.30 | $-0.30 | 0.0% | $234000 | $174600 | +34.0% |
| 2025-05-12 | $-0.25 | $-0.28 | +10.7% | $342000 | $185860 | +84.0% |
| 2025-03-26 | $-0.25 | $-0.26 | +3.8% | $234000 | $277300 | -15.6% |
| 2024-11-12 | $-0.21 | $-0.21 | 0.0% | $369000 | $292762 | +26.0% |
| 2024-08-12 | $-0.17 | $-0.21 | +19.0% | $526000 | $183480 | +186.7% |
| 2024-05-15 | $-0.20 | $-0.30 | +33.3% | $325000 | $368800 | -11.9% |
| 2024-02-15 | $-0.02 | $-0.04 | +50.0% | $337000 | $1.8M | -81.3% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.43M | 7.10M | 10.79M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M | 4.22M |
| Net Income | (79.28M) | (46.51M) | (14.67M) | (7.15M) | (3.19M) | (3.27M) | (4.85M) | (6.70M) | (6.16M) | (4.71M) | (3.68M) | (5.96M) |
| EPS | -1.23 | -0.85 | -0.27 | -0.13 | -0.06 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 |
| Total Assets | 341.10M | 97.89M | 58.09M | 67.25M | 15.51M | 8.70M | 9.42M | 7.46M | 12.27M | 18.10M | 23.00M | 26.55M |
| Total Debt | 4.06M | 2.55M | 0 | 652,000 | 897,000 | 1.00M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 61.58M | 9.24M | 20.99M | 60.35M | 9.59M | 2.39M | 5.33M | 2.60M | 5.93M | 10.14M | 5.23M | 7.68M |
| Operating Cash Flow | (18.29M) | (36.91M) | (12.17M) | (7.71M) | (2.84M) | (3.64M) | (5.05M) | (5.71M) | (5.71M) | (3.88M) | (3.52M) | (3.23M) |
| Free Cash Flow | (72.71M) | (37.98M) | (12.47M) | (7.98M) | (3.22M) | (3.91M) | (5.49M) | (6.05M) | (6.26M) | (4.38M) | (3.67M) | (3.27M) |
| FCF per Share | -1.13 | -0.69 | -0.23 | -0.15 | -0.06 | -0.06 | -0.08 | -0.11 | -0.11 | -0.08 | -0.07 | -0.08 |
| Book Value | 290.67M | 75.18M | 54.64M | 64.39M | 12.77M | 5.72M | 7.68M | 5.03M | 10.60M | 16.40M | 20.78M | 23.96M |
| Cash & ST Investments | 226.92M | 9.24M | 43.76M | 60.35M | 9.59M | 2.39M | 5.33M | 3.42M | 8.97M | 12.39M | 14.59M | 17.68M |
| ROC Equity | -0.27 | -0.62 | -0.27 | -0.11 | -0.25 | -0.57 | -0.63 | -1.33 | -0.58 | -0.29 | -0.18 | -0.25 |